{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:57:42Z","timestamp":1791568662032,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to investigate the clinical features and risk factors of gout attacks during anti\u2010tuberculosis (TB) treatment in South Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We investigated the clinical characteristics of 49 patients who suffered from gout attacks while taking anti\u2010TB medications. Among them, 25 TB patients having newly developed gout attacks without prior history of gout were set to the gout group. Seventy\u2010five age\u2010 and sex\u2010matched TB patients without gout attacks during anti\u2010TB therapy were randomly selected as the control group. The demographics, clinical features, and laboratory findings between the two groups were compared to establish risk factors of gout attack during anti\u2010TB treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The gout patients had a mean age of 67.7\u00a0\u00b1\u00a013.2\u00a0years and 39 patients (79.6%) were male. Approximately half of the patients experienced an attack within 2\u00a0months of treatment initiation. The attacks typically involved lower extremity joints (87.8%). The serum uric acid (SUA) levels were significantly elevated at 2 and 6\u00a0months after starting anti\u2010TB medication compared with those at baseline. In the case\u2010control study, the factors associated with gout attack were higher body mass index (BMI), higher pre\u2010treatment SUA levels, dyslipidemia, and reduced renal function. In the multivariate model, higher BMI, chronic kidney disease (CKD), and pre\u2010treatment hyperuricemia (SUA\u00a0\u2265\u00a06.8\u00a0mg\/dL) were independent risk factors of gout attack while taking anti\u2010TB medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with high BMI, CKD, and pre\u2010treatment hyperuricemia are at a higher risk of gout attack during TB treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13697","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T04:29:24Z","timestamp":1568780964000},"page":"1905-1911","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical features and risk factors for gout attacks during anti\u2010tuberculosis treatment: A case\u2010control study in South Korea"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9523","authenticated-orcid":false,"given":"You\u2010Jung","family":"Ha","sequence":"first","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wan","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-4793","authenticated-orcid":false,"given":"Jae Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Hospital Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Bundang Hospital Seongnam Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-3437","authenticated-orcid":false,"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Seoul National University Hospital Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine Seoul Korea"},{"name":"Department of Molecular Medicine and Biopharmaceutical Sciences Graduate School of Convergence Science and Technology and College of Medicine Medical Research Center Seoul National University Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1315"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22014"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2011.18.2.94"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"e_1_2_8_8_1","first-page":"679","article-title":"Drug\u2010induced hyperuricaemia and gout","volume":"56","author":"Ben Salem C","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(76)90046-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780150411"},{"key":"e_1_2_8_11_1","volume-title":"Global tuberculosis report 2017","author":"World Health Organization","year":"2017"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02474201"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20344"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39254"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(57)90230-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1309\/7GBYQTY62PFEHDP1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(69)90188-0"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000105320.04395.D0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.33.498"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800737200"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197204062861407"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(80)90080-7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200216666150812123725"},{"key":"e_1_2_8_25_1","volume-title":"Korean guidelines for tuberculosis","author":"Joint committee for the revision of Korean guidelines for tuberculosis, Korea centers for disease control and prevention","year":"2017"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_27_1","first-page":"136","article-title":"Pyrazinamide induced hyperuricemia in patients taking anti\u2010tuberculous therapy","volume":"14","author":"Solangi GA","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002401119"},{"key":"e_1_2_8_29_1","first-page":"271","article-title":"Gout secondary to pyrazinamide and ethambutol","volume":"123","author":"Rao TP","year":"1996","journal-title":"Va Med Q"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel268"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.4078\/jkra.2010.17.2.183"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","article-title":"Risk factors for gout and prevention: a systematic review of the literature","volume":"23","author":"Singh JA","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.742"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90346-8"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006843"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13697","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T08:40:19Z","timestamp":1694248819000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/1756-185X.13697"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13697","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"2019-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}